These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 24213770)
1. Precompetitive consortia in biomedicine--how are we doing? Mittleman B; Neil G; Cutcher-Gershenfeld J Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770 [No Abstract] [Full Text] [Related]
2. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness]. Hedner T; Gatenbeck L Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257 [No Abstract] [Full Text] [Related]
3. David Haslam. Interview by Asher Mullard. Haslam D Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976 [No Abstract] [Full Text] [Related]
4. Precompetitive activity to address the biological data needs of drug discovery. Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293 [No Abstract] [Full Text] [Related]
5. Open access chemical and clinical probes to support drug discovery. Edwards AM; Bountra C; Kerr DJ; Willson TM Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100 [TBL] [Abstract][Full Text] [Related]
6. Precompetitive research: a new prescription for drug development? Woodcock J Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454 [No Abstract] [Full Text] [Related]
7. Combating the cons of consolidation. Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592 [No Abstract] [Full Text] [Related]
8. Strategic groups in the biopharmaceutical industry: implications for performance. Erden Z; von Krogh G; Nytorp C; Hultberg M Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760 [TBL] [Abstract][Full Text] [Related]
9. Large drug firms narrow their therapeutic interests. Mullard A Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171 [No Abstract] [Full Text] [Related]
10. Can emerging drug classes improve R&D productivity? Meier C; Cairns-Smith S; Schulze U Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084 [No Abstract] [Full Text] [Related]
11. An audience with...Francis Collins. Interviewed by Asher Mullard. Collins F Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031 [No Abstract] [Full Text] [Related]
12. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665 [TBL] [Abstract][Full Text] [Related]
13. Competition: Unlikely partnerships. Savage N Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391 [No Abstract] [Full Text] [Related]
15. Pfizer's home remedy. Abkowitz A Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588 [No Abstract] [Full Text] [Related]
16. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process. Shimura H; Masuda S; Kimura H Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159 [TBL] [Abstract][Full Text] [Related]
17. Opportunities for vaccine research in Europe. Gancberg D; Hoeveler A; Martini A; Draghia-Akli R Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718 [No Abstract] [Full Text] [Related]
18. Into the valley of death: research to innovation. Hudson J; Khazragui HF Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848 [TBL] [Abstract][Full Text] [Related]
19. Setbacks in Alzheimer research demand new strategies, not surrender. Jobke B; McBride T; Nevin L; Peiperl L; Ross A; Stone C; Turner R; PLoS Med; 2018 Feb; 15(2):e1002518. PubMed ID: 29486005 [TBL] [Abstract][Full Text] [Related]